<DOC>
	<DOCNO>NCT01786707</DOCNO>
	<brief_summary>A prospective , open label , randomize control clinical trial compare benefit hyperbaric oxygen therapy intrapancreatic stem cell infusion standard medical treatment alone type 2 diabetes mellitus . Subjects receive standard medical treatment ( SMT ) insulin metformin 4 month ( evaluation phase ) . Then randomize either intervention group control group :</brief_summary>
	<brief_title>Autologous Stem Cell Hyperbaric Oxygen Therapy Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This phase I/II , prospective , randomized case control study patient Type 2 Diabetes Mellitus ( T2DM ) seek investigate whether combination intrapancreatic Autologous Stem Cell infusion ( ASC ) Hyperbaric Oxygen treatment ( HBO ) improve glycemic control pancreatic function T2DM patient compare control receive standard medical treatment ( SMT ) metformin insulin alone . New therapy lead stop ß-cell damage possible ß-cell regeneration may decrease incidence progression T2DM chronic complication together achievable life style change may improve general health quality life T2DM patient . Preliminary data pilot study involve 25 subject T2DM underwent combine treatment use ASC+HBO show significant progressive consistent reduction plasma glucose HbA1c increase C-peptide conjunction decrease number dose oral agent and/or insulin . These encouraging preliminary result require confirmation control , randomize prospective trial .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Male female patient age 45 65 year age . 2 . Ability provide write informed consent . 3 . Mentally stable able comply procedure study protocol . 4 . Clinical history compatible type 2 diabetes define Expert Committee Diagnosis classification Diabetes Mellitus . 5 . Onset T2DM disease 40 year age . 6 . T2DM duration : 215 year time enrollment . 7 . Basal Cpeptide : 0.3 ng/mL 8 . HbA1c 7.512.5 % standard medical therapy . Patients must treat SMT minimum 4 month prior randomization . Insulin metformin dose stable 3 month prior randomization . 9 . HbA1c : 7.59.5 % time randomization . 10 . Total insulin daily dose baseline randomization &lt; 100 units/day . 1 . BMI &gt; 40 kg/m2 . 2 . Insulin requirement &gt; 100 U/day , HbA1c &gt; 9.5 % 3 . Creactive protein &gt; 10.00 4 . Uncontrolled blood pressure : SBP &gt; 140 mmHg DBP &gt; 80 mmHg Evidence renal dysfunction , serum creatinine &gt; 1.5 mg/dl ( male ) 1.4 mg/dl ( female ) 5 . Proteinuria &gt; 300 mg/day 6 . History EKG evidence myocardial infarction degree heart failure 7 . Female participant : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study . Male participant : intent procreate 3 month intervention unwillingness use effective measure contraception . 8 . Active infection include hepatitis B , hepatitis C , HIV , TB . Positive test acceptable associate history previous vaccination absence sign active infection . 9 . Known active alcohol substance abuse include cigarette/cigar smoking 10 . Baseline Hgb low limit normal local laboratory ; lymphopenia ( &lt; 1,000/L ) , neutropenia ( &lt; 1,500/L ) , thrombocytopenia ( platelet &lt; 100,000/L ) . 11 . A history Factor V deficiency coagulopathy define INR &gt; 1.5 , PTT &gt; 40 , PT &gt; 15 . 12 . Acute chronic pancreatitis . 13 . Symptomatic peptic ulcer disease . 14 . Hyperlipidemia despite medical therapy 15 . Receiving treatment medical condition require chronic use systemic corticosteroid past six month . 16 . Symptomatic cholecystolithiasis . 17 . Use investigational agent within 4 week enrollment . 18 . Admission hospital reason 14 day prior enrollment . 19 . History presence active proliferative diabetic retinopathy macular edema . 20 . Any malignancy . 21 . Hepatic enzyme level upper normal limit . 22 . Total bilirubin upper normal limit unless secondary know benign condition . 23 . Abdominal aortic aneurysm . 24 . History cerebrovascular accident . 25 . Any patient acute subacute decompensation diabetes . 26 . Any acute chronic infectious condition criterion investigator would risk patient . 27 . Hypoproteinemia , cachexia terminal state ; history anorexia/bulimia ; respiratory insufficiency ; history chronic sinusitis ( sinusitis last 8 week past year ) recurrent acute sinusitis ( sinusitis last 4 week four time past year . 28 . Any contraindication hyperbaric oxygen treatment . 29 . Subjects treated medication could interfere outcome study . 30 . Subjects positive autoantibody 31 . History Cushing syndrome ( endogenous iatrogenic ) . 32 . History allergy iodine iodinate material . 33 . Abnormal thyroid function 34 . Any medical condition , opinion investigator , interfere safe completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Hyperbaric oxygen therapy ( HOT )</keyword>
	<keyword>Autologous Bone Marrow-Derived Buffy Coat</keyword>
	<keyword>Stem cell ( SC )</keyword>
</DOC>